Zhen-Peng Jiang

Zhen-Peng Jiang

Auto-generated profile, based on publicly available information

Zhen-Peng Jiang

Department of Nuclear Medicine, Guangzhou First People’s Hospital, School of Medicine, South China University of Technology

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2025 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
YCYou Cheng
You Cheng
ZJZhen-Peng Jiang
Zhen-Peng Jiang
XCXiao-Bo Chen
Xiao-Bo Chen
KLKai-Yu Lu
Kai-Yu Lu
ZLZaiyi Liu
Zaiyi Liu
DSDan Shao
Dan Shao
Objective: This study investigates the predictive value of 18F-FDG PET/CT metabolic parameters in patients with non–small cell lung cancer (NSCLC) undergoing neoadjuvant immunotherapy plus chemotherapy. Methods: We conducted a retrospective analysis of clinical data from 131 patients with pathologically confirmed NSCLC who were deemed resectable after 3 cycles of neoadjuvant immunotherapy plus chemotherapy. Pretreatment and post-treatment PET metabolic parameters were evaluated. CT assessments based on immune response evaluation criteria in solid tumors (iRECIST) were compared with PET/CT assessments using the response criteria in solid tumors (PERCIST). ROC curve analysis and Kaplan-Meier survival analysis, including univariate and Cox multivariate analyses, were employed to assess the prognostic value of PET metabolic parameters after treatment. Results: The PET/CT assessment based on PERCIST showed high consistency with prognosis, while the CT assessment based on iRECIST demonstrated low consistency. Statistically significant differences were observed between the iRECIST and PERCIST criteria (P<0.001). ROC curve analysis revealed significant differences in post-treatment PET metabolic parameters (postSUVmax, postSUVmean, postSUVpeak, postMTV, and postTLG) as well as the percentage changes in metabolic parameters before and after treatment(Δ) (ΔSUVmax, ΔSUVmean, ΔSUVpeak, ΔMTV, and ΔTLG) (P<0.05). Optimal cutoff values enabled stratification into high-risk and low-risk groups. Univariate analysis showed significantly higher survival in the low-risk group for all parameters except ΔMTV (P=0.311), while Cox multivariate analysis identified ΔSUVmax as the most predictive. Conclusions: The PERCIST is more accurate than iRECIST in evaluating prognosis for NSCLC neoadjuvant immunotherapy plus chemotherapy. PET metabolic parameters, particularly ΔSUVmax, effectively predict prognosis and support clinical decision-making.

14 July 2025 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
ZJZhen-Peng Jiang
Zhen-Peng Jiang
HSHui-Min Shan
Hui-Min Shan
HZHao-Yu Zhu
Hao-Yu Zhu
YCYou Cheng
You Cheng
KLKai-Yu Lu
Kai-Yu Lu
DSDan Shao
Dan Shao
Purpose: This study aimed to evaluate the role of various metabolic parameters derived from baseline 18F-FDG PET/CT in predicting the prognosis of stage IV non–small cell lung cancer (NSCLC) patients scheduled to receive osimertinib treatment. Patients and Methods: A retrospective analysis was conducted on 177 NSCLC patients (98 males, 79 females; mean age 58.5 ± 11.0 y) who underwent osimertinib therapy and 18F-FDG PET/CT scanning before treatment. Clinical and PET/CT parameters were assessed, including age, sex, smoking history, brain metastasis, bone metastasis, CEA level, SUVmax, SUVmean, SUVpeak, metabolic tumor volume (MTV), and total lesion glycolysis (TLG). Receiver operating characteristic (ROC) curve analysis was used to calculate the optimal cutoff values for all parameters. Progression-free survival (PFS) was analyzed using log-rank tests, Kaplan-Meier curves, and Cox proportional hazard models to identify prognostic markers. Results: The mean follow-up period was 15.24 ± 8.14 months. Univariate analysis revealed that SUVmax, SUVmean, MTV, and TLG were significantly associated with PFS, with cutoff values of 12.3, 8.57, 13.49 cm3, and 162.37, respectively. The hazard ratios were 1.776 (P = 0.007), 2.155 (P<0.001), 3.312 (P < 0.001), and 3.370 (P < 0.001), respectively. Multivariate survival analysis indicated that MTV was an independent prognostic factor for PFS (HR = 2.323; P = 0.012). Conclusions: Baseline PET/CT metabolic parameters before osimertinib treatment may help identify potential NSCLC patients who could derive clinical benefit, and baseline MTV of the primary tumor from 18F-FDG PET/CT is a reliable prognostic indicator for PFS in stage IV NSCLC patients treated with osimertinib.

1 July 2026 in Quantitative Imaging in Medicine and Surgery
Verified
Journal Article
Open access
PDF file
ZJZhenpeng Jiang
Zhenpeng Jiang
JHJiayan Huang
Jiayan Huang
WBWuyongga Bao
Wuyongga Bao
KZKeyu Zeng
Keyu Zeng
ZWZhe Wu
Zhe Wu
QLQiang Lu
Qiang Lu
Background: According to the American Association for the Study of Liver Diseases (AASLD) 2023 guidelines, contrast-enhanced ultrasound (CEUS) is a valuable complementary imaging modality for characterizing focal liver lesions (FLLs) that are not definitively diagnosed by contrast-enhanced computed tomography (CECT) or contrast-enhanced magnetic resonance imaging (CEMRI). This study compared the washout time of FLLs assessed by quantitative analysis (QA) and visual analysis (VA) on CEUS, evaluated their effects on CEUS Liver Imaging Reporting and Data System (LI-RADS) classification, and assessed their diagnostic performance in hepatocellular carcinoma (HCC). Furthermore, we sought to identify the QA-derived optimal washout time threshold for HCC diagnosis. Methods: Patients at high risk for HCC who underwent CEUS examinations at our hospital between April 2020 and October 2021 were retrospectively enrolled. All FLLs were pathologically confirmed. Washout time was assessed quantitatively using VueBox® software (QA) and visually by radiologists (VA). LR-5 was defined by CEUS LI-RADS (2017) as the category indicating liver lesions that are definitely HCC. QA LR-5 and VA LR-5 were defined as LR-5 categories assigned according to CEUS LI-RADS (version 2017) based on QA and VA, respectively. Furthermore, a modified washout time threshold was applied in the QA group to determine the optimal cutoff for HCC diagnosis, resulting in a new category termed “modified QA LR-5”. The Wilcoxon signed-rank test was used to compare the washout time between QA and VA, and the diagnostic performance of VA LR-5, QA LR-5, and modified QA LR-5 for HCC was compared using the McNemar test. Results: A total of 233 FLLs from 225 patients were included, comprising 220 malignant lesions (184 HCCs) and 13 benign lesions. Median washout time of all FLLs was 55–59 seconds by QA and ≥60 seconds by VA (Z=−6.185, P<0.001). For HCCs, the median washout time was ≥60 seconds with both QA and VA, although QA detected earlier onset (Z=−6.022, P<0.001). For HCC diagnosis, QA LR-5 showed lower sensitivity (51.6% vs. 66.3%, P<0.001), accuracy (60.5% vs. 72.1%, P<0.001) and area under the receiver operating characteristic curve (AUC) (0.728 vs. 0.801, P0.05). With a 40-second threshold, modified QA LR-5 significantly improved in sensitivity (79.9% vs. 66.3%, P<0.001) and accuracy (80.7% vs. 72.1%, P0.05) or AUC (0.818 vs. 0.801, P>0.05) compared with VA LR-5. Conclusions: QA reveals earlier washout than VA, while both methods show good agreement with CEUS LI-RADS classification. Modifying the washout threshold from 60 to 40 seconds significantly improves the diagnostic performance of QA LR-5, supporting recalibration of CEUS LI-RADS for quantitative assessment, likely because QA is more sensitive in detecting early contrast clearance.